title: Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.
abstract: OBJECTIVE
  Rivaroxaban has recently been approved for stroke prevention in atrial fibrillation. However, lack of an effective antidote represents a major concern in the event of intracerebral hemorrhage (ICH). The aims of the present study were to establish a murine model of ICH associated with rivaroxaban, and to examine the effectiveness of different hemostatic factors in preventing excess hematoma expansion.
  
  
  METHODS
  In C57BL/6 mice receiving 10 or 30 mg/kg rivaroxaban by gastric gavage, plasma concentration, prothrombin time, and coagulation factor activities were measured repeatedly. Thirty minutes after inducing ICH by intrastriatal collagenase-injection, mice received an intravenous injection of either saline, prothrombin complex concentrate (100 U/kg), murine fresh frozen plasma (200 μL), or recombinant human Factor VIIa (1 mg/kg). ICH volume was quantified on brain cryosections and using hemoglobin spectrophotometry 24 hours later.
  
  
  RESULTS
  Rivaroxaban in 30 mg/kg dose substantially increased the hematoma volume in ICH induced by 0.060 U collagenase. Prothrombin complex concentrate, fresh frozen plasma, or Factor VIIa prevented excess hematoma expansion caused by anticoagulation. Prevention of hematoma expansion by prothrombin complex concentrate was dose-dependent. None of the 3 agents completely corrected the prolonged prothrombin time, although they restored the activities of deficient FII and X.
  
  
  CONCLUSIONS
  Prothrombin complex concentrate, Factor VIIa, and fresh frozen plasma prevent excess intracerebral hematoma expansion in a murine ICH model associated with rivaroxaban. The efficacy and safety of this reversal strategy must be further evaluated in clinical studies.
authors: Department of Neurology, University Heidelberg, Heidelberg, Germany.
authors: Wei
authors: W
authors: Zhou
authors: Markus
authors: M
authors: Zorn
authors: Peter
authors: P
authors: Nawroth
authors: Ulf
authors: U
authors: Bütehorn
authors: Elisabeth
authors: E
authors: Perzborn
authors: Stefan
authors: S
authors: Heitmeier
authors: Roland
authors: R
authors: Veltkamp
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects*; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use; D006406:Hematoma / Q000517:prevention & control; D006489:Hemostatic Techniques; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D009025:Morpholines / Q000009:adverse effects*; D010949:Plasma; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D001779:Blood Coagulation Factors; D009025:Morpholines; D013876:Thiophenes; C025667:prothrombin complex concentrates; D000069552:Rivaroxaban; D015942:Factor VIIa